English press releases

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,

Peptonic Medical AB (publ) (“Peptonic”) announces that the United States Patent and Trademark Office (“USPTO”) has granted patent (16238.0043U1) for the treatment and prevention of

Peptonic Medical AB (publ) (“Peptonic”) has signed an exclusive distribution agreement with FirstAid4All to launch Peptonic’s products in intimate self-care in Belgium, the Netherlands, and

Peptonic Medical AB (“Peptonic”) clarifies short term strategic priorities under the leadership of its new CEO. Committed to achieving tangible results, the company is prioritizing

Peptonic Medical AB (publ) (“Peptonic”) announced today that Doz Apotek will include the company’s product Vernivia against bacterial vaginosis in the assortment in 51 of

Peptonic Medical AB (publ) (“Peptonic”) is extending the partnership with Farmasiet that will bring the entire VagVital product portfolio to the Norwegian market. Farmasiet, Norway’s

Peptonic Medical AB (publ) (“Peptonic”) announced today that the company’s patented intimate wash, VagiVital Moisturizing V Cleanser, is being offered for sale in 293 Apoteket

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,

Peptonic Medical AB (publ) (”Peptonic”) today announced that the company has signed a non-exclusive distribution agreement with Al Fotune Medical Equipment LLC for United Arab Emirate concerning the product VagiVital VS Pro. ”Al Fotune is a medical device company

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,

Peptonic Medical AB (publ) (“Peptonic”) announced today that the company’s patented product for self-testing of bacterial vaginosis, VagiVital VS, is being offered for sale in

Today, November 2, 2023 the exercise period for warrants of series TO3 begins in PEPTONIC medical AB (“Peptonic” or the “Company”). The exercise period lasts

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,

Peptonic CEO Erik Sundquist presented the company on Biostock Life Summit Event in Lund October 26, 2023. If you were unable to see the event

Peptonic Medical AB (publ) today announced that CEO Erik Sundquist will present the company at the BioStock Life Science Fall Summit in Lund, Sweden, on

Peptonic Medical AB (publ) today announced that it has received its first order in Central America from Windsor Pharmaceuticals. “It is gratifying that Windsor now

Peptonic Medical AB (publ) (“Peptonic”) today announced that it has signed an exclusive agreement regarding VagiVital’s amniotic leak self-test with Savyon Diagnostics (“Savyon”) for the

At an extraordinary general meeting on August 21, Pharmiva’s shareholders approved the planned merger between Peptonic Medical AB (“Peptonic”) and Pharmiva AB (“Pharmiva”). The merger

GROUP 2023 SECOND QUARTER (April-June) 2023 FIRST HALF YEAR (April-June) Message from our CEO Important steps towards establishing a leading Swedish Femtech Company We are

Peptonic Medical AB (publ) today announces that Albert Lindgren has been appointed Chief Financial Officer (CFO) and member of Group Management. He will take up

PEPTONIC Medical AB today announced that the company has signed a license agreement with Swiss medical device company Prima Lab SA for the sale of

Peptonic Medical AB (publ) today announces that the Stockholm District Court has rejected the Swedish Economic Crime Authority’s (EBM) claim for a corporate fine for

The FemTech companies PEPTONIC medical AB (“Peptonic”), listed on Spotlight Stock Market, and Pharmiva AB (publ) (“Pharmiva”), listed on Nasdaq First North Growth Market, have

Peptonic Medical AB (publ) today announced that the application to patent its intimate cleanser in US will be approved on June 20th2023, this according to

Peptonic Medical AB (publ) today announced that an arbitration court in China has ruled in favor of Peptonic in a dispute with Yuanjia Biotechnology Co., Ltd.

PEPTONIC Medical AB announces that the company has signed a license agreement with Swiss medical technology company Prima Lab SA regarding self-tests for urinary tract

Peptonic Medical AB (publ) today announced that the company has signed an exclusive agreement with Cetro Medical for distribution of VagiVital VS Pro and VagiVital AL

Peptonic Medical (PMED:SS) today announced that it has signed a non-exclusive agreement with the medical technology company Siemens Healthineers for the distribution of Peptonic’s portfolio of diagnostic

The Nomination Committee of Peptonic Medical AB (publ) presents the following proposals for resolutions at the Annual General Meeting on May 24 2023, regarding the number of

GROUP 2022 FOURTH QUARTER (oct-dec) FULL YEAR 2022 (jan-dec) Before inventory adjustments that fully charge quarter 4 instead of being distributed over previous quarters. From

Peptonic Medical (publ) announced today that its wholly owned daughter company Lune Oy Ltd has signed a marketing collaboration agreement with a Swedish company Peak

Peptonic Medical (publ) announced today that it has signed a Distribution Agreement with UCC Australia for the Australian market concerning 5 items in the Lunette

Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Group, Peptonic Medical Israel Ltd and CommonSense Marketing Inc are included from 2021-10-20. 2021 Fourth

Peptonic Medical (publ) announced today that it is now introducing VagiVital®️ range of hormone free treatments to the US market. VagiVital long term vision is to

The Company has previously announced that the Swedish Economic Crime Authority initiated an investigation in 2020 regarding a serious insider crime due to measures that

Peptonic Medical (publ) announced today that its wholly owned daughter company Lune Oy Ltd has signed a joint promotion agreement with American company Womanizer. A

At the Annual General Meeting on June 30, 2021, it was decided that the Chairman of the Board will contact the three largest shareholders in

Peptonic Medical (publ) announced today that LloydsApotek is expanding its distribution with three more products from Peptonic’s range. LloydsApotek operates 75 pharmacies in about 40

Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03 Peptonic Medical AB (publ) org nr 556776-3064 (www.spotlightstockmarket.com ticker: PMED) Group, Lune Group

Peptonic Medical AB (publ) (“PMED” or “the Company”) announces today, November 4th , 2021, the intention to carry out a rights issue of units consisting of shares

Peptonic Medical (publ) today announced that the company has signed a contract amendment with Orion Corporation in Finland. The amendment concerns Peptonic’s Moisturizing V Cleanser

The acquisition also includes the US-registered subsidiary CommonSense Marketing Inc, based in New York. During year 2020 CommenSense had sales of approximately $ 2 million. CommonSense

CommonSense has been under public administration since 2021-07-07. The company is focused on women’s health and has, among other things, CE-marked products for self-testing of

Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03. Peptonic Medical AB (publ) org nr 556776-3064(www.aktietorget.se ticker: PMED). Group, Lune Group OY

Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs that the distribution agreement with Yuanjia Biotechnology Co., Ltd. concerning VagiVital® AktivGel for the Chinese market has

Peptonic Medical AB (publ) (‘Peptonic’ or ‘the Company’) today announces that the Company has received approval from the Swedish Medical Products Agency as well as

Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs that the latest clinical study with VagiVital® has been published. The objective of the study was to

The annual general meeting in PEPTONIC medical AB (publ), corp. reg. no 556776-3064 (the “Company”) was held on 27 May 2021 by postal voting whereby

Peptonic Medical (publ) (“Peptonic” or “The Company”) today announced that two new products will be added under Lunette® brand. Lunette, the female, founder-led brand, created revolutionary Period

Peptonic Medical (publ) (“Peptonic” or “The Company”) today announced that Kronans Apotek launches VagiVital® Moisturizing V Cleanser in 236 of its physical stores in Sweden. Kronans Apotek

Peptonic Medical (publ) (“Peptonic” or “Bolaget”) today announced it has signed a distributor agreement with Revisage concerning sales and distribution of VagiVital® AktivGel in Poland. Revisage

Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03. 2021 first quarter

The Board of Directors of Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’ today announces that Erik Sundquist is appointed as new CEO after Johan Inborr.

Peptonic Medical AB (publ) (‘Peptonic’ or ‘the Company’) today announces the launch of a in-house developed intimate wash – VagiVital V cleanser – which is

Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03. Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Group, Lune Group

Peptonic Medical AB (publ) (‘Peptonic’ or ‘the company’) has announced the appointment of Mikael Svensson, a strategic and operational leader, to the position of General

The Board of Directors of Peptonic Medical AB (the “Company”) hereby announces that the Company’s issue of shares with preferential rights of approximately SEK 25.4

Peptonic Medical AB (publ) (‘Peptonic’ or ‘the company’) announces today that they have signed an agreement with Common Sense, Ltd. (Common Sense) on the distribution

Peptonic Medical AB (publ) org nr 556776-3064(www.aktietorget.se ticker: PMED). Group, Lune Group OY incl subsidiary is included from 2020-06-03 2020 Third quarter (Jul-Sep) Net sales

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) today announced that it has exercised the option to obtain a loan of 7.5 MSEK from Vidarstiftelsen according

Peptonic Medical AB (publ) (‘Peptonic’ or ‘Company’) announces today that the Company has submitted an application for patent protection for the treatment of genital fungal

Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs about the results of the latest clinical study with VagiVital®. The objective of this study was to

Peptonic Medical (publ) (‘Peptonic’ or ‘Company’) today announced the results of a customer survey that was performed during spring/early summer this year among VagiVital users.

Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Group, Lune Group OY incl subsidiary is included from 2020-06-03. 2020 second quarter (Apr-Jun) Net

Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has received a purchase order from its Chinese partner Shijiazhuang Yuanjia Biotechnology  Co. Ltd. (“Yuanjia Bio”) for

The extra ordinary shareholder’s meeting resolved to approve the decision by the Board of Directors to exercise the option to acquire the remaining outstanding shares

In connection with the acquisition of a majority of the shares in Lune Group Oy (“Lune”), Peptonic was granted a call option to acquire the

On 14 May 2020, Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announced that the Company had entered into an agreement to acquire a majority

Peptonic Medical AB (publ) org nr 556776-3064(www.spotlightstockmarket.se ; ticker: PMED) 2020 first quarter (Jan-Mar) Net sales of products KSEK 1,781 (1,477) Gross profit KSEK 985 (802),

Peptonic Medical AB (publ) (’Peptonic’ or ’Company’) today announced that it has filed a patent application for and intimate wash based on the Company’s vaginal

Peptonic Medical AB (publ) (‘Peptonic’ or the ‘Company’) today announced that the Company has filed a patent application concerning the use of its self-care vaginal

The Board of Directors of Peptonic Medical (publ) (“Peptonic” or “The Company”) has decided to postpone the Annual General Meeting (AGM), for the second time,

Peptonic Medical AB (‘Peptonic’ or ’Company’) today announces that its self-care product VagiVital® will be available for purchase in all eighty LloydsApotek’s retail shops in Sweden

The Board of Directors of Peptonic Medical (publ) (“Peptonic” or “The Company”) has decided to postpone the Annual General Meeting (AGM) with a view to

Peptonic Medical AB (publ) org nr 556776-3064 (www.spotlightstockmarket.com , ticker: PMED). 2019 fourth quarter (Oct-Dec) Net sales of products KSEK 394 (263) Gross profit KSEK 321 (137),

Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has submitted a so called 510k application to the US Food and Drug Adminstration (FDA) to

Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has received a purchase order from its Chinese partner Shijiazhuang Yuanjia Biotechnology  Co. Ltd. (“Yuanjia Bio”) for

Peptonic Medical AB (‘Peptonic’ or ‘Company’) today announces that Kronans Apotek and Apoteksgruppen have decided to carry Peptonic’s self-care product VagiVital® in 170 and 37 of their

Peptonic Medical AB (‘Peptonic’ or ‘Company’) today announces that it has closed a private placement transaction with Vidarstiftelsen. The transaction comprised 11 million shares at

Peptonic Medical AB (‘Peptonic’ or ‘Company’) today announces that it has entered an agreement with Skyflair Asia concerning the on-line marketing and sale of VagiVital® (‘Product’)

Peptonic Medical AB (‘Peptonic’ or ‘Company’) today announces that it has commenced the sale of VagiVital® (‘Product’) in the United Kingdom. From today, the Product can

Peptonic Medical AB (“Peptonic” or “Company”) today announced that that the DQS Medizine GmbH (DQS-MED) certification committee has approved the takeover of the CE mark concerning

In accordance with previously announced plans (e.g. interim report dated August 16th, 2019) Peptonic Medical AB (publ) (‘Peptonic’ or ‘Company’) today announced that it has

Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has entered an agreement with Shijiazhuang Yuanjia Biotechnology Co. Ltd. (“Yuanjia Bio”) concerning the registration,

Peptonic Medical AB (“Peptonic” or “Company”) today announced that it has entered an agreement with DQS Medizine GmbH (DQS-MED) which means that DQS-MED will become

The last day of trading in the company’s shares PMED including the right to receive subscription rights is May 23, 2019. The first day excluding

2019 first quarter (Jan-Mar) Net sales of products KSEK 1,470 (0) Gross profit KSEK 802 (0), Gross margin 55% (0%) Operating loss KSEK -3,185 (-2,756) 

Peptonic Medical AB (publ) (‘Peptonic’ or ‘Company’) today announced that during May Apoteket AB will expand the distribution of Peptonic’s self-care product VagiVital® from today’s 30

With reference to today’s press release from Spotlight, the trading in PEPTONIC Medical AB’s share PMED will resume today, May 9, 2019 at 09:00. Information